Compare Archer Aviation Inc (ACHR) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer Aviation Inc vs Adaptive Biotechnologies Corp — how do they compare? Archer Aviation Inc trades at $6.29 (market cap $5.23B), while Adaptive Biotechnologies Corp trades at $24.9 (market cap $4.04B). The key difference: Archer Aviation Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.
| ACHR | ADPT | |
|---|---|---|
Market Cap | $5.23B | $4.04B |
Sector | Industrials | Health |
52-Week High | $13.64 | $25.45 |
52-Week Low | $4.44 | $12.30 |
Enterprise Value | $3.79B | $4.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $6.30, up 0.64% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 revenue beat but sustained heavy losses, with a net income margin of -11,589.86% in 2026. Recent news highlights a strategic deal with Boeing to acquire three businesses, broadening its defense and AI aviation portfolio, which fueled a significant stock rally.
The outlook remains speculative with high execution risks amid substantial cash burn, but analyst sentiment is strongly bullish (77.78% buy ratings) due to regulatory progress and Boeing's backing. Key risks include dilution from equity offerings, certification delays, and profitability challenges in the nascent eVTOL market.
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer Aviation Inc
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
